Impact Factor
4.56
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
12.14
6,159 total citations
h5-index
117
h5 depth signal
Cited share
53.9%
284 of 527
Total citations
6,159
Citation footprint
Metric signal
12.85
External metric anchor
Self-citation
1.6%
101 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
616
United Kingdom
544
Australia
227
Italy
221
China
206
Citing Fields of Research
Digestive Disorders
649
Hepatitis
628
Liver Diseases
426
Inflammatory Bowel Diseases & Infections
363
Liver & Colon Cancer
314
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,481
Articles tracked across the journal lifetime
Indexed publication set
527
284 cited publications
Last 12 months
219
18.3 publications/month
Open access share
5.5%
12 OA publications in the last year
Leading citing country
United States
616 citing publications
Leading citing field
Digestive Disorders
649 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v2n1, Jan. 2017-
v2n1, Jan. 2017- ; Selected citations only before this date
Research Focus & Classification
Indexed Subjects
Inflammatory Bowel Diseases & Infections
Hepatitis
Liver Diseases
Digestive Disorders
Broad Categories
Gastroenterology
Digestive Disorders
Hepatitis
Inflammatory Bowel Diseases & Infections
Liver & Colon Cancer
MeSH Descriptors
Gastrointestinal Diseases
Liver Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/s2468-1253(26)00149-4
Open DOI
Strategies to develop therapeutic cancer vaccines for pancreatic cancer
02
DOI 10.1016/s2468-1253(26)00274-8
Open DOI
Research in Brief
03
DOI 10.1016/s2468-1253(26)00273-6
Open DOI
Baveno VIII: what's new?
04
DOI 10.1016/s2468-1253(26)00270-0
Open DOI
Correction to Lancet Gastroenterol Hepatol 2025; 10: 537–49
05
DOI 10.1016/s2468-1253(26)00268-2
Open DOI
Validation of Rome V for irritable bowel syndrome – Authors’ reply
06
DOI 10.1016/s2468-1253(26)00267-0
Open DOI
Lessons from the TRIPLET-HCC trial – Authors’ reply
07
DOI 10.1016/s2468-1253(26)00266-9
Open DOI
Validation of Rome V for irritable bowel syndrome
08
DOI 10.1016/s2468-1253(26)00261-x
Open DOI
Validation of Rome V for irritable bowel syndrome
09
DOI 10.1016/s2468-1253(26)00242-6
Open DOI
Adjuvant chemoradiotherapy or completion total mesorectal excision after local excision of rectal cancer – Authors’ reply
10
DOI 10.1016/s2468-1253(26)00240-2
Open DOI
Tackling the global liver disease syndemic through primary care in the Asia-Pacific region
Bibliographical & Catalog Notes
Volume 1 complete in 4 issues.
Numbering from contents page.